Olema Oncology, Inc. OLMA
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Olema Oncology, Inc. (OLMA) is a healthcare company listed in the US with a market value of about $662M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -30%.
About Olema Oncology
Olema Oncology is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 118% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$162M | -$129M | -$97M | -$105M | -$71M | -$22M | -$4M |
| Free cash flow | — | -$105M | — | -$82M | -$52M | -$20M | — |
| EPS (diluted) | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 | $-3.42 | $-1.66 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -29.2% | -27.4% | -32.4% | -42.2% | -19.6% | -5.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $35.50, 370% above the current price; targets range from $13.00 to $59.00; the consensus rating is “Strong buy”; expected EPS is $-2.56 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Olema Oncology pay a dividend?
Not currently.
Is Olema Oncology a good stock to buy?
We do not give buy or sell advice. Olema Oncology scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.